Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.

ABSTRACT: BACKGROUND:Treatment with fingolimod reduces inflammation in multiple sclerosis (MS) by inhibiting lymphocyte egress from lymph nodes. We aimed to map, in detail, the alterations in peripheral blood lymphocyte subpopulations in relation to clinical outcome in MS patients treated with fingolimod. METHODS:Paired blood samples from relapsing-remitting MS patients (n = 19) were collected before and after one year of treatment with fingolimod (0.5 mg/day). Absolute counts and relative proportions of a broad set of T- B- and NK-cell subsets were analyzed by flow cytometry. Blood samples from 18 healthy controls were used for baseline comparisons. RESULTS:Treatment with fingolimod markedly decreased the absolute numbers of all major lymphocyte subsets, except for NK cells. The reduction was most

SUBMITTER: Hjorth M 

PROVIDER: S-EPMC6996838 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature